Targeting HER-2 over expressed breast cancer cells with 2-cyclohexyl-N-[(Z)-(substituted phenyl/furan-2-yl/thiophene-2-yl)methylidene]hydrazinecarbothioamide

Bioorg Med Chem Lett. 2015 Jan 1;25(1):83-7. doi: 10.1016/j.bmcl.2014.11.009. Epub 2014 Nov 10.

Abstract

Cyclohexyl thiosemicarbazone derivatives (C1-14) were synthesized, characterized and evaluated against HER-2 over expressed breast cancer cells. The synthesized compounds were screened in vitro against four breast cancer cell lines; SKBr-3, MCF-7, MDA-MB-468 and MDA-MB-231. All the compounds showed activity against HER-2 over expressed SKBr-3 cells with (IC₅₀ = 25.6 ± 0.07 μM-61.6 ± 0.4 μM). The most active compounds inhibit ALDH⁺ breast cancer stem cells more effectively than the cancer stem cells specific agent Salinomycin. Immunohistochemistry staining also confirmed that these compounds inhibit the expression of HER-2 on SKBr-3 cells. Compound C2 significantly inhibited the cell migration and cell adhesion of breast cancer cell lines. Compound C2 was found to most active compound of this series targeting HER-2 over expressed breast cancer cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / metabolism*
  • Drug Delivery Systems / methods*
  • Female
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • MCF-7 Cells
  • Receptor, ErbB-2 / antagonists & inhibitors*
  • Receptor, ErbB-2 / biosynthesis*
  • Thiosemicarbazones / administration & dosage
  • Thiosemicarbazones / chemical synthesis*

Substances

  • Thiosemicarbazones
  • ERBB2 protein, human
  • Receptor, ErbB-2